Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

A clinician describes using 9LA as a trial for patients with many asymptomatic brain metastases, checking intracranial response at one-month intervals and avoiding whole-brain radiation when possible. Carbone agrees 9LA patients with or without brain metastases did just as well, and one speaker reports sustained responses over a year.

Related Insights

Due to the high likelihood of long-term survival with modern targeted therapies, whole brain radiation (WBRT) is considered contraindicated for patients with EGFR-mutated lung cancer, irrespective of brain metastases count. The risk of severe neurocognitive decline outweighs any benefit, making systemic therapy and SRS preferred.

Modern practice is shifting away from routine Prophylactic Cranial Irradiation (PCI) for extensive-stage small cell lung cancer. This change is driven by a key Japanese study where patients, screened with baseline MRI, showed a survival trend favoring observation with serial MRIs over PCI, challenging a long-standing treatment paradigm.

Beyond overall response rates, a critical area of excitement for new ADCs in lung cancer is their potential to treat brain metastases. Early data showing hints of intracranial efficacy is a significant point of interest, as this addresses a common and difficult-to-treat site of disease progression, offering a potential advantage over other therapies.

With new CNS-active drugs dramatically improving survival after a brain metastasis diagnosis, some experts are now advocating for routine screening brain MRIs in high-risk patients. The goal is to detect asymptomatic lesions early, potentially preventing catastrophic neurologic events like seizures.

For HER2+ gastric cancer patients with a single brain metastasis that is fully resected and radiated, experts may opt for close monitoring. This watch-and-wait approach is preferred over immediate systemic adjuvant therapy, even in this high-risk scenario.

Triple-negative breast cancer brain metastases frequently present alongside aggressive visceral disease, making pauses for local brain therapy challenging. Emerging trial data indicate topoisomerase-1-directed ADCs penetrate the central nervous system effectively, showing prolonged activity in both parenchymal brain metastases and leptomeningeal disease.

Zongertinib shows a meaningful intracranial response rate of ~44% in HER2-mutant NSCLC. This efficacy supports initiating systemic TKI therapy for patients with small, asymptomatic brain metastases and monitoring closely with short-interval scans, potentially avoiding or delaying brain radiation and its associated toxicities.

An expert questions the utility of PCI, arguing that historical studies supporting its use were flawed because they lacked baseline brain MRIs. This means many patients may have been treated for existing, not prophylactic, metastases. Modern MRI surveillance may be a better approach to avoid long-term radiation toxicity in survivors.

For EGFR-mutated NSCLC patients with brain metastases, even numerous ones (>30), potent systemic therapy like osimertinib plus chemotherapy is often initiated first. This can achieve high rates of complete intracranial response, allowing clinicians to delay or entirely avoid whole-brain radiation and its long-term toxicities.

For TNBC patients with newly discovered, asymptomatic brain metastases, the practical approach is to start systemic therapy immediately while planning for CNS-directed treatment. This contrasts with strict clinical trial protocols that require CNS treatment and stabilization first, which can dangerously delay systemic control of extracranial disease.